HF
URGN icon

HRT Financial’s UroGen Pharma URGN Stock Holding History

HRT Financial’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-49,363
Closed -$887K – 5395
2026
Q1 		$887K Sell
49,363
-81,536
-62% -$1.63M ﹤0.01% 2139
2025
Q4 		$3.06M Sell
130,899
-2,775
-2% -$60.2K 0.01% 1031
2025
Q3 		$2.67M Buy
133,674
+29,448
+28% +$529K 0.01% 992
2025
Q2 		$1.43M Buy
+104,226
New +$1M 0.01% 1081
2023
Q2 		– Sell
-60,623
Closed -$560K – 3314
2023
Q1 		$560K Buy
+60,623
New +$558K 0.01% 1283

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

HRT Financial's URGN Position: Q2 2026 in Review

HRT Financial sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 49,363 shares — an estimated $887K sold.

HRT Financial first reported a position in URGN in Q1 2023 and held it in 5 quarters. The position peaked at $3.06M in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • HRT Financial reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 49,363 UroGen Pharma shares in Q2 2026, an estimated $887K.
  • HRT Financial first reported a position in UroGen Pharma in Q1 2023 and held it in 5 quarters.
  • HRT Financial's UroGen Pharma position peaked at $3.06M in Q4 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.